Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cisplatin.

E E Trimmer1, J M Essigmann

  • 1Department of Chemistry, Massachusetts Institute of Technology, Cambridge 02139, USA.

Essays in Biochemistry
|March 24, 2000
PubMed
Summary
This summary is machine-generated.

Cisplatin is an effective anti-cancer drug, forming DNA adducts that trigger cell death. Its isomer, trans-DDP, is ineffective, highlighting the importance of cisplatin

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens.

Gut·2009
Same author

Design, synthesis, and evaluation of estradiol-linked genotoxicants as anti-cancer agents.

Bioorganic & medicinal chemistry letters·2004
Same author

Design of DNA damaging agents that hijack transcription factors and block DNA repair.

Advances in experimental medicine and biology·2002
Same author

Effect of sequence context on O(6)-methylguanine repair and replication in vivo.

Biochemistry·2001
Same author

Recognition of cisplatin adducts by cellular proteins.

Mutation research·2001
Same author

Mechanisms of resistance to cisplatin.

Mutation research·2001
Same journal

Intra- and inter-biosynthetic gene cluster allelic variation as drivers of chemical diversification in Streptomyces.

Essays in biochemistry·2026
Same journal

Considering internal conflict in the face of natural product biosynthesis and biosynthetic gene cluster evolution.

Essays in biochemistry·2026
Same journal

The plant holobiont: integrating molecular priming and ecological legacies for climate-adaptive immunity.

Essays in biochemistry·2026
Same journal

Bacterial-fungal interactions: connections and consequences.

Essays in biochemistry·2026
Same journal

Invasive plasmids as ecosystem engineers-from mechanism to application.

Essays in biochemistry·2026
Same journal

From early defence priming to lasting memory: developmental and seasonal dynamics in trees.

Essays in biochemistry·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Cisplatin is a crucial chemotherapy agent, particularly for testicular cancer.
  • Its efficacy stems from DNA adduct formation, causing structural distortions and apoptosis.
  • The geometric isomer, trans-diamminedichloroplatinum(II) (trans-DDP), lacks therapeutic activity.

Purpose of the Study:

  • To elucidate the mechanisms underlying cisplatin's anti-tumor activity and resistance.
  • To investigate the differential binding of cellular proteins to cisplatin- and trans-DDP-induced DNA adducts.
  • To understand the role of DNA repair pathways in cisplatin cytotoxicity.

Main Methods:

  • Analysis of DNA adduct formation by cisplatin and trans-DDP.
  • Investigation of DNA replication and transcription inhibition.

Related Experiment Videos

  • Assessment of programmed cell death (apoptosis) induction.
  • Study of the nucleotide-excision-repair pathway's role.
  • Examination of high-mobility group (HMG) domain protein binding to DNA adducts.

    • Main Results:

    • Cisplatin forms DNA adducts (intrastrand and interstrand crosslinks) that distort DNA structure.
    • These adducts inhibit DNA replication and transcription, leading to apoptosis.
    • Both cis- and trans-DDP adducts are substrates for the nucleotide-excision-repair pathway.
    • HMG domain proteins selectively bind to cisplatin-modified DNA, not trans-DDP-modified DNA.
    • Mechanisms of cisplatin resistance, both intrinsic and acquired, have been identified.

    Conclusions:

    • Cisplatin's anti-cancer activity is mediated by specific DNA adducts that trigger cytotoxic pathways.
    • Selective binding of cellular proteins like HMG domain proteins to cisplatin adducts may modulate its efficacy.
    • Understanding cisplatin resistance mechanisms is crucial for improving cancer therapy outcomes.